GMDP augments antitumor action of the CP/TNFα combination in vivo

Abstract We have shown that glucosaminyl muramyl dipeptide (GMDP) has been augmented the antitumor action of chemotherapy drug cisplatin and tumor necrosis factor-α (TNFα) on the Ehrlich ascites carcinoma and melanoma B-16 mouse tumor models. The doses of cisplatin, TNFα and GMDP and also the condit...

Full description

Saved in:
Bibliographic Details
Published inBiomedicine & pharmacotherapy Vol. 64; no. 4; pp. 240 - 248
Main Authors Petrova, Elena E, Simonova, Maria A, Komaleva, Ravilya L, Britsina, Marina V, Andronova, Tatiana M, Nesmeyanov, Vladimir A, Valyakina, Tatiana I
Format Journal Article
LanguageEnglish
Published Elsevier SAS 01.04.2010
Subjects
Chemotherapy
Glucosaminyl muramyl dipeptide
Internal Medicine
Medical Education
Tumor necrosis factor
Tumor necrosis factor
Glucosaminyl muramyl dipeptide
Chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Abstract We have shown that glucosaminyl muramyl dipeptide (GMDP) has been augmented the antitumor action of chemotherapy drug cisplatin and tumor necrosis factor-α (TNFα) on the Ehrlich ascites carcinoma and melanoma B-16 mouse tumor models. The doses of cisplatin, TNFα and GMDP and also the conditions of the drugs combination injection provided 100% survival of mice with Ehrlich ascites carcinoma were found. Furthermore, it was shown first that GMDP has been decreased toxicity of the cisplatin/TNFα combination and normalized the changes in the experimental mice hematological parameters which were produced by the CP/TNFα combination.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2009.06.019